
    
      This was a Phase I, randomized, placebo-controlled, double-blinded, dose ranging study
      designed to assess the safety, tolerability, and immunogenicity of C. difficile vaccine. The
      study was conducted in healthy male and female adults, 18 to 55 years old. Subjects was
      randomly assigned on Day 0 to receive one of two doses of C. difficile vaccine (50 or 100
      mcg) or placebo (vehicle control containing alum).
    
  